<DOC>
	<DOCNO>NCT01114568</DOCNO>
	<brief_summary>The purpose study examine rate extent absorption three oral formulation ertugliflozin ( PF 04971729 , MK-8835 ) administer lean obese healthy volunteer .</brief_summary>
	<brief_title>Study To Estimate The Relative Bioavailability Ertugliflozin ( PF-04971729 , MK-8835 ) Healthy Adult Participants ( MK-8835-039 )</brief_title>
	<detailed_description />
	<criteria>Healthy male and/or female subject age 21 65 year , inclusive ( Healthy define clinically relevant abnormality identify detailed medical history , full physical examination , include blood pressure pulse rate measurement , 12 lead ECG clinical laboratory test ) . Women must non childbearing potential Body Mass Index ( BMI ) 18.5 35.4 kg/m2 ; total body weight &gt; 50 kg ( 110 lb ) . An informed consent document sign date subject . Subjects willing able comply schedule visit , treatment plan , laboratory test , study procedure . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease ( include drug allergy , exclude untreated , asymptomatic , seasonal allergy time screen ) . Any condition possibly affect drug absorption ( eg , gastrectomy ) . A positive urine drug screen Screening prior dose Period 1 . History regular alcohol consumption exceed 14 drinks/week female 21 drinks/week male ( 1 drink = 5 ounce ( 150 mL ) wine 12 ounce ( 360 mL ) beer 1.5 ounce ( 45 mL ) hard liquor ) within 6 month screen .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Relative Bioavailability</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Pharmacodynamics</keyword>
</DOC>